Andrea Mambrini - Catalysis

Author Information

Andrea Mambrini is a researcher affiliated with the Department of Pharmaceutical Sciences, specifically within the Group of Catalysis, Synthesis and Organic Green Chemistry, at the University of Perugia, located in Perugia, Italy. His research profile indicates a focus on various aspects of cancer research, including genetic variants linked to pancreatic cancer risk and innovative treatment methods for locally advanced pancreatic cancer.

Research Contributions

Andrea Mambrini has made significant contributions to the field of cancer research. In 2021 alone, he published several papers addressing crucial topics such as genetic variants associated with pancreatic cancer risk, new treatment methodologies like open radiofrequency ablation and modulated electro-hyperthermia, and the role of next-generation genomic sequencing in cancer treatment. His research spans a wide array of studies, including the synthesis of complex organic compounds and subgroup analyses of cancer therapies, highlighting his multidisciplinary approach to tackling cancer.

Aliases

Andrea Mambrini is also known by the aliases A Mambrini and A. Mambrini.

Publication and Citation Metrics

Metric	Value
Total Citations	3214
H-index	28
Total Papers	215

Publications:

Identification of recessively inherited genetic variants for pancreatic cancer risk

DOI: 10.1016/j.pan.2021.05.161

Year: 2021

Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial.

DOI: 10.1016/j.pan.2021.06.005

Year: 2021

A three-component [3 + 2]-cycloaddition/elimination cascade for the synthesis of spirooxindole-pyrrolizines.

DOI: 10.1039/d0ob02321c

Year: 2021

Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk

DOI: 10.3389/fonc.2021.771312

Year: 2021

Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients

DOI: 10.5306/wjco.v12.i11.1064

Year: 2021

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

DOI: 10.1016/j.ejca.2021.01.051

Year: 2021

Association of genetic variants affecting microRNAs and pancreatic cancer risk

DOI: 10.1016/j.pan.2021.05.162

Year: 2021

Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk

DOI: 10.3389/fgene.2021.693933

Year: 2021

Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.

DOI: 10.1016/j.pan.2021.04.004

Year: 2021

Onco-Esthetics Dilemma: Is There a Role for Electrocosmetic-Medical Devices?

DOI: 10.3389/fonc.2020.528624

Year: 2020

What are Catalytically Active Species?

Why is Addition Rate Important?

What Are the Common Tools Used in Catalysis?

How Is PSA Integrated into a Catalytic Process?

What are Process Upsets?

How Does Oxy Fuel Combustion Work?

What Are Some Examples of Biometric Catalysts?

What are the Challenges to Achieving Transparency?

What are the Different Scales in Catalysis?

What is Fermentation?

Partnered Content Networks

Relevant Topics